人民卫生出版社系列期刊
ISSN 2096-2738 CN 11-9370/R

中国科技核心期刊（中国科技论文统计源期刊）
2020《中国学术期刊影响因子年报》统计源期刊
美国化学文摘社（CAS）数据库收录期刊
日本科学技术振兴机构（JST）数据库收录期刊

新发传染病电子杂志

新发传染病电子杂志 ›› 2025, Vol. 10 ›› Issue (1): 22-26.doi: 10.19871/j.cnki.xfcrbzz.2025.01.005

• 论著 • 上一篇    下一篇

广西地区585例耐多药/利福平耐药结核患者的治疗转归影响因素分析

吕柳英1, 梁月新2, 张凯1, 曾慧频1, 黄丽花3, 黄俊理1, 刘爱梅4   

  1. 1.广西壮族自治区胸科医院公共卫生科,广西柳州 545005;
    2.广西壮族自治区胸科医院三甲办,广西柳州 545005;
    3.广西壮族自治区胸科医院检验科,广西柳州 545005;
    4.广西壮族自治区胸科医院院长办公室,广西柳州 545005
  • 收稿日期:2024-07-21 出版日期:2025-02-28 发布日期:2025-03-31
  • 通讯作者: 刘爱梅,Email：gxltyyliu@163.com
  • 基金资助:
    1.广西科技重大专项（桂科AA22096027）;2.广西医疗卫生适宜技术开发与推广应用项目（S2022041）

Analysis of factors affecting treatment outcomes in 585 multidrug-resistant/rifampicin-resistant tuberculosis patients in Guangxi area

Lyu Liuying1, Liang Yuexin2, Zhang Kai1, Zeng Huipin1, Huang Lihua3, Huang Junli1, Liu Aimei4   

  1. 1. Public Health Department of Guangxi Zhuang Autonomous Region Chest Hospital, Guangxi Liuzhou 545005, China;
    2. Department of Grade A Tertiary Hospital Management, Guangxi Chest Hospital, Guangxi Liuzhou 545005, China;
    3. Department of Laboratory Medicine, Guangxi Chest Hospital, Guangxi Liuzhou 545005, China;
    4. Office of the President, Guangxi Chest Hospital, Guangxi Liuzhou 545005, China
  • Received:2024-07-21 Online:2025-02-28 Published:2025-03-31

PDF

31

摘要： 目的 分析广西地区2019–2021年耐多药/利福平耐药结核（multidrug-resistant and rifampicin-resistant tuberculosis,MDR/RR-TB）患者治疗、转归情况的影响因素,为耐药结核治疗和防控提供数据支持。方法 采用回顾性研究方法,收集2019–2021年在广西壮族自治区胸科医院就诊的585例MDR/RR-TB患者的临床资料及治疗转归情况,分析MDR/RR-TB患者治疗转归的影响因素。结果 MDR/RR-TB患者的总体治疗成功率为53.33%,2019–2021年度分别为51.02%、53.30%、54.98%。治疗转归情况的主要影响因素有性别、年龄、人群分类、治疗分类、药物不良反应、合并糖尿病和合并肺部疾病（P<0.05）。男性、年龄>24岁、出现药物不良反应和合并糖尿病的MDR/RR-TB患者更易出现不良转归（P<0.05）。结论 广西地区MDR/RR-TB治疗取得一定成效,2019–2021年治疗成功率呈上升趋势。治疗和督导需重点关注男性、老年人、有药物不良反应、合并糖尿病的患者,加强药物不良反应的监测,提高耐药结核的成功治疗率。

关键词: 利福平耐药结核, 耐多药结核, 影响因素, 成功治疗

Abstract: Objective This study aims to analyze the factors influencing the treatment outcomes of multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) patients in Guangxi from 2019 to 2021, providing data support for the treatment and prevention of drug-resistant tuberculosis. Method A retrospective study was conducted to collect clinical data and treatment outcomes for 585 MDR/RR-TB patients who visited a tuberculosis hospital in Guangxi during the specified period. The analysis focused on the impact of various factors on the treatment outcomes of these patients. Result The overall treatment success rate for MDR/RR-TB patients was 53.33%, with annual rates of 51.02%, 53.30%, and 54.98% from 2019 to 2021, respectively. The main factors influencing treatment outcomes included gender, age, population classification, treatment classification, adverse drug reactions, and the presence of comorbidities such as diabetes and lung disease (P<0.05), male patients, those over 24 years old, patients with adverse drug reactions, and those with diabetes were more likely to have poor treatment outcomes(P<0.05). Conclusion The treatment of MDR/RR-TB in Guangxi has shown promising results, with an increasing treatment success rate from 2019 to 2021. Future treatment and supervision efforts should prioritize male patients, the elderly, those experiencing adverse drug reactions, and patients with diabetes, while also enhancing the monitoring of adverse drug reactions to improve the treatment success rate for drug-resistant tuberculosis.

Key words: Rifampicin-resistant tuberculosis, Multidrug-resistant tuberculosis, Influencing factors, Successful treatment

中图分类号: 

本系统由北京玛格泰克科技发展有限公司设计开发 技术支持：support@magtech.com.cn